Mechanisms of pyruvate inhibition of oxidant-induced apoptosis in human endothelial cells

Microvasc Res. 2003 Sep;66(2):91-101. doi: 10.1016/s0026-2862(03)00052-9.

Abstract

We have recently demonstrated that the redox reactant pyruvate prevents hydrogen peroxide (H2O2)-induced endothelial apoptosis and that its anti-apoptotic feature is mediated partially through the mitochondrial compartment. However, little is known about molecular signal pathways that mediate the anti-apoptotic feature of pyruvate. A biochemical approach to elucidate such signal pathways was attempted in human umbilical vein endothelial cells (HUVECs). Effects of antioxidant pyruvate were compared with those of cytosolic reductant L-lactate, redox-neutral acetate, and malate-aspartate shuttle blocker aminooxyacetate. Various indices of endothelial apoptosis were correlated with cell viability. Submillimolar H2O2 caused >50% cell killing, as manifested by its oxidant insult. The massive cell death induced by H2O2 was inhibited by pyruvate but not by L-lactate or aminooxyacetate, suggesting a role of cytosolic NADH reducing equivalents, possibly via stimulated oxidant generation. The induction and nuclear translocation of p53 by H2O2 was blocked by pyruvate and appeared to be somewhat enhanced by L-lactate or aminooxyacetate in association with oxidant generation. Nuclear translocation of p53 accompanied the transactivation of bax and downregulation of bcl-2. The pyruvate-related redox manipulation inhibited the H2O2-induced p53 activation, restored the downregulated bcl-2 and the upregulated bax, and hence enhanced the bcl-2/bax expression ratio. In contrast, L-lactate, acetate, or aminooxyacetate had no such effect. These results indicate that pyruvate could modulate key regulatory signal pathways in cytosol and mitochondrial matrix, thereby inactivating endothelial death pathways. Furthermore, it is suggested that stabilizing the expression of bcl-2 and bax genes by metabolic antioxidants may be an effective strategy for endothelial protection against oxidative stress.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetates / pharmacology
  • Aminooxyacetic Acid / pharmacology
  • Antioxidants / metabolism
  • Apoptosis / drug effects*
  • Cell Nucleus / drug effects
  • Cell Nucleus / metabolism
  • Cell Survival / drug effects
  • Cells, Cultured
  • Cytosol / metabolism
  • Dose-Response Relationship, Drug
  • Endothelium, Vascular / cytology*
  • Endothelium, Vascular / drug effects
  • Humans
  • Hydrogen Peroxide / pharmacology
  • Infant, Newborn
  • Lactic Acid / pharmacology
  • Models, Biological
  • Oxidants / pharmacology
  • Oxidation-Reduction
  • Oxidative Stress / drug effects
  • Oxidative Stress / physiology*
  • Proto-Oncogene Proteins / genetics
  • Proto-Oncogene Proteins / metabolism
  • Proto-Oncogene Proteins c-bcl-2 / genetics
  • Proto-Oncogene Proteins c-bcl-2 / metabolism
  • Pyruvic Acid / metabolism*
  • Pyruvic Acid / pharmacology
  • Signal Transduction
  • Transcriptional Activation
  • Tumor Suppressor Protein p53 / drug effects
  • Tumor Suppressor Protein p53 / metabolism
  • Umbilical Veins / cytology
  • bcl-2-Associated X Protein

Substances

  • Acetates
  • Antioxidants
  • BAX protein, human
  • Oxidants
  • Proto-Oncogene Proteins
  • Proto-Oncogene Proteins c-bcl-2
  • Tumor Suppressor Protein p53
  • bcl-2-Associated X Protein
  • Aminooxyacetic Acid
  • Lactic Acid
  • Pyruvic Acid
  • Hydrogen Peroxide